CAS NO: | 1276553-09-3 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 380.4 |
Formula | C18H13FN6OS |
CAS No. | 1276553-09-3 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 76 mg/mL (199.8 mM) |
Water:<1 mg/mL | |
Ethanol: 7 mg/mL warming (18.4 mM) | |
Solubility (In vivo) | Suspended in 0.5% methylcellulose: 1mg/mL |
Chemical Name / Synonym | 4-(4-cyano-2-fluorophenyl)-2-morpholino-5-(1H-1,2,4-triazol-3-yl)thiophene-3-carbonitrile; PF4989216; PF 4989216; PF-4989216 |
In Vitro | Kinase Assay: PF-4989216 (Compound 10) has excellent PI3Kα Ki (0.6 nM), good cellular potency (S473 IC50=79 nM), and good selectivity against mTOR (mTOR Ki=1440 nM). PF-4989216 has PI3Kα Ki less than 1 nM and mTOR Ki more than 1 μM. PF-4989216 also has excellent selectivity over 40 other kinases, and no major CYP inhibitions are observed. Less than 30% inhibition is observed in 1A2, 2C9, 2D6, and 3A4 CYP enzymes at 3 μM. Cell Assay: SCLC cells are cultured (5,000 cells/well) in a 96-well microtiter plate at 37°C in 5% CO2 in supplier-recommended growth media and compounds are added to each well starting at 10 μM with a 3-fold serial dilution. At 72 hours after compound addition, CellTiter-Glo (CTG) Solution is added per the manufacturer's instructions. Luminescence is read on an Envision plate reader. All experiments are run in duplicate and have been repeated at least three times. Cells NCI-H69, NCI-H1048, NCI-H1436, NCI-H82, NCI-H254, NCI-H526, NCI-H1963, NCI-H146, NCI-H841, Lu99A, Lu134B, and Lu134A cells. PF-4989216 significantly inhibits cell viability in SCLC cells with a PIK3CA mutation, such as NCI-H69, NCI-H1048, and Lu99A cells. PF-4989216, via PI3K signaling inhibition, blocks cell-cycle progression and reduces cell transformation in SCLCs. In SCLCs with PIK3CA mutation, PF-4989216 induces BIM-mediated apoptosis. |
---|---|
In Vivo | In SCID mice bearing NCI-H69 or NCI-H1048 xenograft tumors, PF-4989216 (350 mg/kg, p.o.) inhibits PI3K phosphorylation signaling and induces antitumor activity. |
Animal model | SCID mice bearing NCI-H69 or NCI-H1048 xenograft tumors |
Formulation & Dosage | Dissolved in in 0.5% methylcellulose; 350 mg/kg; oral administration |
References | [1] Walls M, et al. Clin Cancer Res. 2014, 20(3), 631-643. |
PF-4989216 inhibited PI3K downstream signaling in SCLC cells. Clin Cancer Res. 2014, 20(3), 631-643. | PF-4989216 inhibited PI3K phosphorylation signaling and induced antitumor activity in NCI-H1048 xenograft models. Clin Cancer Res. 2014, 20(3), 631-643. | PF-4989216 inhibited PI3K phosphorylation signaling and induced antitumor activity in NCI-H1048 xenograft models. Clin Cancer Res. 2014, 20(3), 631-643. |